Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32597466.
- Also identified by DOI 10.1093/cid/ciaa879 and PMC identifier 7337637.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
Medical subject headings
- COVID-19 Drug Treatment